Komboglyze: new hypoglycaemic combination

Bristol-Myers Squibb and AstraZeneca have launched Komboglyze, a fixed-dose combination of saxagliptin and metformin.

The combination tablet is taken twice daily at mealtimes.

The tablets are licensed for use in patients with type II diabetes inadequately controlled by metformin alone and in those currently receiving the combination as separate tablets, or with insulin when insulin plus metformin is inadequate.

Komboglyze provides fixed doses of two hypoglycaemic agents with complementary mechanisms of action: saxagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.

Greater HBA1c reduction than placebo

In a 12-week study, 160 patients whose blood glucose levels were not adequately controlled by metformin alone were randomised to receive placebo or saxagliptin 2.5mg twice daily in addition to metformin.

After 12 weeks, patients in the saxagliptin plus metformin group had a greater reduction in HbA1c than those in the placebo plus metformin group (0.6% vs 0.2%, p=NS).

Efficacious in combination with insulin

In another study, 455 patients with diabetes inadequately controlled by insulin or insulin plus metformin were randomised to receive saxagliptin 5mg or placebo as add-on therapy. After 24 weeks, significant improvements in HbA1c and postprandial glucose were observed in the saxagliptin add-on group compared with the placebo group.

View Komboglyze drug record

Further information: BMS/AstraZeneca

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head
Pseudoephedrine written

Pseudoephedrine prescribing information to highlight rare brain disorder risk

Safety information for pseudoephedrine products will...

New generics tracker

New generics - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest generic drugs...